2023

Bhandari, S. et al. (2023) Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. Journal of Nephrology, (doi: 10.1007/s40620-023-01571-6) (PMID:36995528) (PMCID:PMC10061401) (Early Online Publication)

Dawson, J. et al. (2023) Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. EClinicalMedicine, 57, 101863. (doi: 10.1016/j.eclinm.2023.101863)

Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Thomson, P. C. et al. (2022) An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. Kidney International Reports, 7(8), pp. 1793-1801. (doi: 10.1016/j.ekir.2022.05.008)

2021

Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)

Ford, I. et al. (2021) Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. European Heart Journal: Quality of Care and Clinical Outcomes, 7(3), pp. 287-294. (doi: 10.1093/ehjqcco/qcz070) (PMID:31922541)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

MacDonald, T. M., Nuki, G., Robertson, M., Ford, I. and Mackenzie, I. S. (2021) Cardiovascular safety of febuxostat - Authors' reply. Lancet, 398(10304), pp. 955-956. (doi: 10.1016/S0140-6736(21)01383-0) (PMID:34509228)

2020

Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)

Macdougall, I. C. et al. (2020) Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology, 31(4), 2019090972. (doi: 10.1681/ASN.2019090972) (PMID:32253271)

2018

Tayal, B. et al. (2018) Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes. Journal of the American College of Cardiology, 71(12), pp. 1325-1333. (doi: 10.1016/j.jacc.2018.01.042) (PMID:29566816)

2017

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J. , Ford, I. and Ray, K. K. (2017) Low-density lipoprotein-cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein-cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation, 136(20), pp. 1878-1891. (doi: 10.1161/CIRCULATIONAHA.117.027966) (PMID:28877913)

Bax, J. J. et al. (2017) Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. European Heart Journal, 38(10), pp. 720-726. (doi: 10.1093/eurheartj/ehw506)

Nägele, M. P. et al. (2017) Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. European Journal of Heart Failure, 19(1), pp. 80-87. (doi: 10.1002/ejhf.655) (PMID:27862715)

2016

Steffel, J. et al. (2016) Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex. Circulation: Arrhythmia and Electrophysiology, 9(6), e003924. (doi: 10.1161/circep.115.003924) (PMID:27282848)

Böhm, M., Robertson, M., Borer, J., Ford, I. , Komajda, M., Mahfoud, F., Ewen, S., Swedberg, K. and Tavazzi, L. (2016) Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) trial. Journal of the American Heart Association, 5(2), e002160. (doi: 10.1161/JAHA.115.002160) (PMID:26873681) (PMCID:PMC4802472)

Gorcsan, J. et al. (2016) Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. European Heart Journal, 37(1), pp. 49-59. (doi: 10.1093/eurheartj/ehv418) (PMID:26321238)

Dawson, J. et al. (2016) Safety, feasibility, and efficacy of vagus nerve stimulation paired with upper-limb rehabilitation after ischemic stroke. Stroke, 47(1), pp. 143-150. (doi: 10.1161/STROKEAHA.115.010477) (PMID:26645257) (PMCID:PMC4689175)

2015

Böhm, M., Robertson, M., Ford, I. , Borer, J. S., Komajda, M., Kindermann, I., Maack, C., Lainscak, M., Swedberg, K. and Tavazzi, L. (2015) Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction With Ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology, 116(12), pp. 1890-1897. (doi: 10.1016/j.amjcard.2015.09.029) (PMID:26508709)

Steffel, J. et al. (2015) The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal, 36(30), pp. 1983-1989. (doi: 10.1093/eurheartj/ehv242) (PMID:26009595)

Ford, I. , Robertson, M., Komajda, M., Böhm, M., Borer, J. S., Tavazzi, L. and Swedberg, K. (2015) Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology, 184, pp. 163-169. (doi: 10.1016/j.ijcard.2015.02.001) (PMID:25703424)

Loeffen, R., Winckers, K., Ford, I. , Jukema, J. W., Robertson, M., Stott, D. J. , Spronk, H. M., ten Cate, H. and Lowe, G. (2015) Associations between thrombin generation and the risk of cardiovascular disease in elderly patients: results from the PROSPER study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 70(8), pp. 982-988. (doi: 10.1093/gerona/glu228) (PMID:25540034)

2014

Akao, H. et al. (2014) ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis, 235(1), pp. 176-181. (doi: 10.1016/j.atherosclerosis.2014.04.030) (PMID:24854628)

Komajda, M., Böhm, M., Borer, J. S., Ford, I. , Robertson, M., Manolis, A. J., Tavazzi, L. and Swedberg, K. (2014) Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure, 16(7), pp. 810-816. (doi: 10.1002/ejhf.114)

Voors, A. A., van Veldhuisen, D. J., Robertson, M., Ford, I. , Borer, J. S., Bohm, M., Komajda, M., Swedberg, K. and Tavazzi, L. (2014) The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 16(4), pp. 426-434. (doi: 10.1002/ejhf.59)

Borer, J.S., Böhm, M., Ford, I. , Robertson, M., Komajda, M., Tavazzi, L. and Swedberg, K. (2014) Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT Study). American Journal of Cardiology, 113(3), pp. 497-503. (doi: 10.1016/j.amjcard.2013.10.033)

McConnachie, A. , Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C.J. , Cobbe, S.M. and Ford, I. (2014) Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal, 35(5), pp. 290-298. (doi: 10.1093/eurheartj/eht232)

2013

Tavazzi, L., Swedberg, K., Komajda, M., Böhm, M., Borer, J.S., Lainscak, M., Robertson, M. and Ford, I. (2013) Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology, 170(2), pp. 182-188. (doi: 10.1016/j.ijcard.2013.10.068)

Fox, K. et al. (2013) Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 34(29), pp. 2263-2270. (doi: 10.1093/eurheartj/eht101)

Reil, J.-C., Robertson, M., Ford, I. , Borer, J., Komajda, M., Swedberg, K., Tavazzi, L. and Bohm, M. (2013) Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. European Journal of Heart Failure, 15(9), pp. 1044-1052. (doi: 10.1093/eurjhf/hft072)

2012

Swedberg, K., Komajda, M., Bohm, M., Borer, J., Robertson, M., Tavazzi, L. and Ford, I. (2012) Effects on outcomes of heart rate reduction by Ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart Failure Treatment with I-f inhibitor ivabradine Trial) Study. Journal of the American College of Cardiology, 59(22), pp. 1938-1945. (doi: 10.1016/j.jacc.2012.01.020)

Akao, H. et al. (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 220(2), pp. 413-417. (doi: 10.1016/j.atherosclerosis.2011.09.028)

Akao, H. et al. (2012) KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 220(2), pp. 456-462. (doi: 10.1016/j.atherosclerosis.2011.11.037)

Petrie, C.J., Voors, A.A., Robertson, M., van Veldhuisen, D.J. and Dargie, H.J. (2012) A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study. Clinical Research in Cardiology, 101(1), pp. 29-35. (doi: 10.1007/s00392-011-0360-x)

Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J. and McMurray, J.J.V. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine, 9(9), e1001310. (doi: 10.1371/journal.pmed.1001310) (PMID:23028261) (PMCID:PMC3445446)

2011

Tendera, M., Talajic, M., Robertson, M., Tardif, J.-C., Ferrari, R., Ford, I. , Steg, P.G. and Fox, K. (2011) Safety of Ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology, 107(6), pp. 805-811. (doi: 10.1016/j.amjcard.2010.10.065)

Wensley, F. et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal, 342, d548-d548. (doi: 10.1136/bmj.d548)

Ceconi, C. et al. (2011) Effect of heart rate reduction by ivabradine on left ventricular remodelling in the echocardiographic substudy of BEAUTIFUL. International Journal of Cardiology, 146(3), pp. 408-414. (doi: 10.1016/j.ijcard.2010.10.125)

Freeman, D. J. et al. (2011) Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics, 11, 8. (doi: 10.1186/1471-2318-11-8) (PMID:21342490) (PMCID:PMC3053238)

Li, Y. et al. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1), pp. 17-23. (doi: 10.1007/s00439-010-0892-6)

2010

Iakoubova, O.A. et al. (2010) KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(4), pp. 455-461. (doi: 10.1097/HJR.0b013e328336a0dd)

Ford, I. , Robertson, M., Shepherd, J. and Cobbe, S. (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 375(9726), pp. 1634-1639. (doi: 10.1016/S0140-6736(10)60545-4)

Caslake, M.J. et al. (2010) Lipoprotein-associated phospholipase A₂ inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 210(1), pp. 28-34. (doi: 10.1016/j.atherosclerosis.2009.10.041)

Polisecki, E. et al. (2010) Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 51(5), pp. 1201-1207. (doi: 10.1194/jlr.P001172)

Matthan, N.R., Resteghini, N., Robertson, M., Ford, I. , Shepherd, J., Packard, C. , Buckley, B.M., Jukema, J.W., Lichenstein, A.H. and Schaefer, E.J. (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 51, pp. 202-209. (doi: 10.1194/jlr.M900032-JLR200)

Welsh, P. et al. (2010) Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach. Journal of Clinical Endocrinology and Metabolism, 95(1), pp. 93-99. (doi: 10.1210/jc.2009-1064)

Stott, D.J. et al. (2010) Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), pp. 605-611. (doi: 10.1161/ATVBAHA.109.199448)

2009

Fox, K., Ford, I. , Steg, G., Tendera, M., Robertson, M. and Ferrari, R. (2009) Relationship between Ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal, 30(19), pp. 2337-2345. (doi: 10.1093/eurheartj/ehp358)

Shepherd, J., Lowe, G., Ford, I. and Robertson, M. (2009) Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Statistics in Medicine, 28(7), pp. 1067-1092. (doi: 10.1002/sim.3530)

Stott, D.J., Welsh, P.I., Rumley, A., Robertson, M., Ford, I. , Sattar, N.A., Westendorp, R.G.J., Jukema, J.W., Cobbe, S. and Lowe, G.D. (2009) Adipocytokines and risk of stroke in older people: a nested case-control study. International Journal of Epidemiology, 38(1), pp. 253-261. (doi: 10.1093/ije/dyn215)

2008

Bloor, M., McIntosh, J., McKeganey, N. and Robertson, M. (2008) Topping up methadone: An analysis of patterns of heroin use among a treatment sample of Scottish drug users. Public Health, 122(10), pp. 1013-1019. (doi: 10.1016/j.puhe.2008.01.007)

Fox, K., Ford, I. , Steg, P.G., Tendera, M., Robertson, M. and Ferrari, R. (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, 372(9641), pp. 817-821. (doi: 10.1016/S0140-6736(08)61171-X)

Polisecki, E. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response and cardiovascular disease incidence in PROSPER. Atherosclerosis, 200(1), pp. 109-114.

Bloor, M., Robertson, M., McKeganey, N. and Neale, J. (2008) Theorising equipment-sharing in a cohort of Scottish drug users. Health, Risk and Society, 10(6), pp. 599-607. (doi: 10.1080/13698570802533697)

McIntosh, J., Bloor, M. and Robertson, M. (2008) The health benefits of reductions in individuals use of illegal drugs. Journal of Substance Use, 13(4), pp. 247-254. (doi: 10.1080/14659890701802836)

Poliseckia, E. et al. (2008) Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 200(1), pp. 95-101. (doi: 10.1016/j.atherosclerosis.2007.12.005)

2007

Neale, J., Robertson, M. and Bloor, M. (2007) Treatment experienced and treatment naive drug agency clients compared. International Journal of Drug Policy, 18(6), pp. 486-493. (doi: 10.1016/j.drugpo.2006.10.005)

Fonarow, G., Lukas, M., Robertson, M., Colucci, W. and Dargie, H. (2007) Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American Heart Journal, 154, pp. 637-644. (doi: 10.1016/j.ahj.2007.06.002)

2006

O'Reilly, D., Upton, M.N., Caslake, M.J., Robertson, M., Norrie, J., McConnachie, A. , Watt, G.C.M. and Packard, C.J. (2006) Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. Heart, 92(4), pp. 533-535. (doi: 10.1136/hrt.2005.063081)

Kemp, P., Neale, J. and Robertson, M. (2006) Homelessness among problem drug users: prevalence, risk factors and trigger events. Health and Social Care in the Community, 14, pp. 319-328. (doi: 10.1111/j.1365-2524.2006.00624.x)

McKeganey, N., Bloor, M., Robertson, M., Neale, J. and MacDougall, J. (2006) Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study. Drugs: Education, Prevention, and Policy, 13, pp. 537-550. (doi: 10.1080/09687630600871987)

2005

McKeganey, N., Neale, J. and Robertson, M. (2005) Physical and sexual abuse among drug users contacting drug treatment services in Scotland. Drugs: Education, Prevention, and Policy, 12, pp. 223-232. (doi: 10.1080/09687630412331317998)

McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. and Ford, I. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction - Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, pp. 525-530.

McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, N. and Ford, I. (2005) Antiarrythmic effect of carvedilol after acute myocardial infarction. Journal of the American College of Cardiology, 45(4), pp. 525-530. (doi: 10.1016/j.jacc.2004.09.076)

Neale, J. and Robertson, M. (2005) Recent life problems and non-fatal overdose among heroin users entering treatment. Addiction, 100, pp. 168-175. (doi: 10.1111/j.1360.0443.2004.00920.x)

Packard, C.J. et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112, pp. 3058-3065. (doi: 10.1161/CIRCULATIONAHA.105.526848)

2004

Cook, G., Clark, R., Morris, T., Robertson, M., Lucie, N., Anderson, S., Paul, J. and Franklin, I. (2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and clexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126(6), pp. 792-798. (doi: 10.1111/j.1365-2141.2004.05127.x)

McKeganey, N., Morris, Z., Neale, J. and Robertson, M. (2004) What are drug users looking for when they contact drug services: abstinence or harm reduction? Drugs: Education, Prevention, and Policy, 11, pp. 423-435. (doi: 10.1080/09687630410001723229)

Neale, J. and Robertson, M. (2004) Recent cocaine and crack use among new drug treatment clients in Scotland. Drugs: Education, Prevention, and Policy, 11, pp. 79-90. (doi: 10.1080/0968763031000140183)

2003

Neale, J. and Robertson, M. (2003) Comparisons of self-report data and oral fluid testing in detecting drug use amongst new treatment clients. Drug and Alcohol Dependence, 71, pp. 57-64. (doi: 10.1016/S0376-8716(03)00053-X)

2002

Little, S.A., Sproule, M.W., Cowan, M.D., Macleod, K.J., Robertson, M., Love, J.G., Chalmers, G.W., McSharry, C. and Thomson, N. (2002) High resolution computed tomography assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax, 57(3), pp. 247-253. (doi: 10.1136/thorax.57.3.247)

Little, S., Sproule, M., Cowan, M., MacLeod, K., Robertson, M., Love, J., Chalmers, G., McSharry, C. and Thomson, N. (2002) High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax, 57, pp. 247-253.

1999

Millett, D.T., Hallgren, A., Fornell, A.C. and Robertson, M. (1999) Bonded molar tubes: a retrospective evaluation of clinical performance. American Journal of Orthodontics and Dentofacial Orthopedics, 115(6), pp. 667-674.

1998

Millett, D.T., Hallgren, A., Cattanach, D., McFadzean, R., Pattison, J., Robertson, M. and Love, J. (1998) A 5-year clinical review of bond failure with a light cured resin adhesive. Angle Orthodontist, 68(4), pp. 351-356.

1996

Baxter, G.M., Aitchison, F., Sheppard, D., Moss, J., McLeod, M.J., Harden, P.N., Love, J.G., Robertson, M. and Taylor, G. (1996) Colour doppler ultrasound in renal artery stenosis: intrarenal waveform analysis. British Journal of Radiology, 69(825), pp. 810-815. (doi: 10.1259/0007-1285-69-825-810)

Articles

Bhandari, S. et al. (2023) Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. Journal of Nephrology, (doi: 10.1007/s40620-023-01571-6) (PMID:36995528) (PMCID:PMC10061401) (Early Online Publication)

Dawson, J. et al. (2023) Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. EClinicalMedicine, 57, 101863. (doi: 10.1016/j.eclinm.2023.101863)

Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Thomson, P. C. et al. (2022) An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. Kidney International Reports, 7(8), pp. 1793-1801. (doi: 10.1016/j.ekir.2022.05.008)

Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)

Ford, I. et al. (2021) Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. European Heart Journal: Quality of Care and Clinical Outcomes, 7(3), pp. 287-294. (doi: 10.1093/ehjqcco/qcz070) (PMID:31922541)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

MacDonald, T. M., Nuki, G., Robertson, M., Ford, I. and Mackenzie, I. S. (2021) Cardiovascular safety of febuxostat - Authors' reply. Lancet, 398(10304), pp. 955-956. (doi: 10.1016/S0140-6736(21)01383-0) (PMID:34509228)

Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)

Macdougall, I. C. et al. (2020) Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology, 31(4), 2019090972. (doi: 10.1681/ASN.2019090972) (PMID:32253271)

Tayal, B. et al. (2018) Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes. Journal of the American College of Cardiology, 71(12), pp. 1325-1333. (doi: 10.1016/j.jacc.2018.01.042) (PMID:29566816)

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J. , Ford, I. and Ray, K. K. (2017) Low-density lipoprotein-cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein-cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation, 136(20), pp. 1878-1891. (doi: 10.1161/CIRCULATIONAHA.117.027966) (PMID:28877913)

Bax, J. J. et al. (2017) Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. European Heart Journal, 38(10), pp. 720-726. (doi: 10.1093/eurheartj/ehw506)

Nägele, M. P. et al. (2017) Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. European Journal of Heart Failure, 19(1), pp. 80-87. (doi: 10.1002/ejhf.655) (PMID:27862715)

Steffel, J. et al. (2016) Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex. Circulation: Arrhythmia and Electrophysiology, 9(6), e003924. (doi: 10.1161/circep.115.003924) (PMID:27282848)

Böhm, M., Robertson, M., Borer, J., Ford, I. , Komajda, M., Mahfoud, F., Ewen, S., Swedberg, K. and Tavazzi, L. (2016) Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) trial. Journal of the American Heart Association, 5(2), e002160. (doi: 10.1161/JAHA.115.002160) (PMID:26873681) (PMCID:PMC4802472)

Gorcsan, J. et al. (2016) Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. European Heart Journal, 37(1), pp. 49-59. (doi: 10.1093/eurheartj/ehv418) (PMID:26321238)

Dawson, J. et al. (2016) Safety, feasibility, and efficacy of vagus nerve stimulation paired with upper-limb rehabilitation after ischemic stroke. Stroke, 47(1), pp. 143-150. (doi: 10.1161/STROKEAHA.115.010477) (PMID:26645257) (PMCID:PMC4689175)

Böhm, M., Robertson, M., Ford, I. , Borer, J. S., Komajda, M., Kindermann, I., Maack, C., Lainscak, M., Swedberg, K. and Tavazzi, L. (2015) Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction With Ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology, 116(12), pp. 1890-1897. (doi: 10.1016/j.amjcard.2015.09.029) (PMID:26508709)

Steffel, J. et al. (2015) The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal, 36(30), pp. 1983-1989. (doi: 10.1093/eurheartj/ehv242) (PMID:26009595)

Ford, I. , Robertson, M., Komajda, M., Böhm, M., Borer, J. S., Tavazzi, L. and Swedberg, K. (2015) Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology, 184, pp. 163-169. (doi: 10.1016/j.ijcard.2015.02.001) (PMID:25703424)

Loeffen, R., Winckers, K., Ford, I. , Jukema, J. W., Robertson, M., Stott, D. J. , Spronk, H. M., ten Cate, H. and Lowe, G. (2015) Associations between thrombin generation and the risk of cardiovascular disease in elderly patients: results from the PROSPER study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 70(8), pp. 982-988. (doi: 10.1093/gerona/glu228) (PMID:25540034)

Akao, H. et al. (2014) ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis, 235(1), pp. 176-181. (doi: 10.1016/j.atherosclerosis.2014.04.030) (PMID:24854628)

Komajda, M., Böhm, M., Borer, J. S., Ford, I. , Robertson, M., Manolis, A. J., Tavazzi, L. and Swedberg, K. (2014) Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure, 16(7), pp. 810-816. (doi: 10.1002/ejhf.114)

Voors, A. A., van Veldhuisen, D. J., Robertson, M., Ford, I. , Borer, J. S., Bohm, M., Komajda, M., Swedberg, K. and Tavazzi, L. (2014) The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 16(4), pp. 426-434. (doi: 10.1002/ejhf.59)

Borer, J.S., Böhm, M., Ford, I. , Robertson, M., Komajda, M., Tavazzi, L. and Swedberg, K. (2014) Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT Study). American Journal of Cardiology, 113(3), pp. 497-503. (doi: 10.1016/j.amjcard.2013.10.033)

McConnachie, A. , Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C.J. , Cobbe, S.M. and Ford, I. (2014) Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal, 35(5), pp. 290-298. (doi: 10.1093/eurheartj/eht232)

Tavazzi, L., Swedberg, K., Komajda, M., Böhm, M., Borer, J.S., Lainscak, M., Robertson, M. and Ford, I. (2013) Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology, 170(2), pp. 182-188. (doi: 10.1016/j.ijcard.2013.10.068)

Fox, K. et al. (2013) Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 34(29), pp. 2263-2270. (doi: 10.1093/eurheartj/eht101)

Reil, J.-C., Robertson, M., Ford, I. , Borer, J., Komajda, M., Swedberg, K., Tavazzi, L. and Bohm, M. (2013) Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. European Journal of Heart Failure, 15(9), pp. 1044-1052. (doi: 10.1093/eurjhf/hft072)

Swedberg, K., Komajda, M., Bohm, M., Borer, J., Robertson, M., Tavazzi, L. and Ford, I. (2012) Effects on outcomes of heart rate reduction by Ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart Failure Treatment with I-f inhibitor ivabradine Trial) Study. Journal of the American College of Cardiology, 59(22), pp. 1938-1945. (doi: 10.1016/j.jacc.2012.01.020)

Akao, H. et al. (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 220(2), pp. 413-417. (doi: 10.1016/j.atherosclerosis.2011.09.028)

Akao, H. et al. (2012) KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 220(2), pp. 456-462. (doi: 10.1016/j.atherosclerosis.2011.11.037)

Petrie, C.J., Voors, A.A., Robertson, M., van Veldhuisen, D.J. and Dargie, H.J. (2012) A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study. Clinical Research in Cardiology, 101(1), pp. 29-35. (doi: 10.1007/s00392-011-0360-x)

Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J. and McMurray, J.J.V. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine, 9(9), e1001310. (doi: 10.1371/journal.pmed.1001310) (PMID:23028261) (PMCID:PMC3445446)

Tendera, M., Talajic, M., Robertson, M., Tardif, J.-C., Ferrari, R., Ford, I. , Steg, P.G. and Fox, K. (2011) Safety of Ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology, 107(6), pp. 805-811. (doi: 10.1016/j.amjcard.2010.10.065)

Wensley, F. et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal, 342, d548-d548. (doi: 10.1136/bmj.d548)

Ceconi, C. et al. (2011) Effect of heart rate reduction by ivabradine on left ventricular remodelling in the echocardiographic substudy of BEAUTIFUL. International Journal of Cardiology, 146(3), pp. 408-414. (doi: 10.1016/j.ijcard.2010.10.125)

Freeman, D. J. et al. (2011) Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics, 11, 8. (doi: 10.1186/1471-2318-11-8) (PMID:21342490) (PMCID:PMC3053238)

Li, Y. et al. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1), pp. 17-23. (doi: 10.1007/s00439-010-0892-6)

Iakoubova, O.A. et al. (2010) KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(4), pp. 455-461. (doi: 10.1097/HJR.0b013e328336a0dd)

Ford, I. , Robertson, M., Shepherd, J. and Cobbe, S. (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 375(9726), pp. 1634-1639. (doi: 10.1016/S0140-6736(10)60545-4)

Caslake, M.J. et al. (2010) Lipoprotein-associated phospholipase A₂ inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 210(1), pp. 28-34. (doi: 10.1016/j.atherosclerosis.2009.10.041)

Polisecki, E. et al. (2010) Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 51(5), pp. 1201-1207. (doi: 10.1194/jlr.P001172)

Matthan, N.R., Resteghini, N., Robertson, M., Ford, I. , Shepherd, J., Packard, C. , Buckley, B.M., Jukema, J.W., Lichenstein, A.H. and Schaefer, E.J. (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 51, pp. 202-209. (doi: 10.1194/jlr.M900032-JLR200)

Welsh, P. et al. (2010) Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach. Journal of Clinical Endocrinology and Metabolism, 95(1), pp. 93-99. (doi: 10.1210/jc.2009-1064)

Stott, D.J. et al. (2010) Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), pp. 605-611. (doi: 10.1161/ATVBAHA.109.199448)

Fox, K., Ford, I. , Steg, G., Tendera, M., Robertson, M. and Ferrari, R. (2009) Relationship between Ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal, 30(19), pp. 2337-2345. (doi: 10.1093/eurheartj/ehp358)

Shepherd, J., Lowe, G., Ford, I. and Robertson, M. (2009) Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Statistics in Medicine, 28(7), pp. 1067-1092. (doi: 10.1002/sim.3530)

Stott, D.J., Welsh, P.I., Rumley, A., Robertson, M., Ford, I. , Sattar, N.A., Westendorp, R.G.J., Jukema, J.W., Cobbe, S. and Lowe, G.D. (2009) Adipocytokines and risk of stroke in older people: a nested case-control study. International Journal of Epidemiology, 38(1), pp. 253-261. (doi: 10.1093/ije/dyn215)

Bloor, M., McIntosh, J., McKeganey, N. and Robertson, M. (2008) Topping up methadone: An analysis of patterns of heroin use among a treatment sample of Scottish drug users. Public Health, 122(10), pp. 1013-1019. (doi: 10.1016/j.puhe.2008.01.007)

Fox, K., Ford, I. , Steg, P.G., Tendera, M., Robertson, M. and Ferrari, R. (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, 372(9641), pp. 817-821. (doi: 10.1016/S0140-6736(08)61171-X)

Polisecki, E. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response and cardiovascular disease incidence in PROSPER. Atherosclerosis, 200(1), pp. 109-114.

Bloor, M., Robertson, M., McKeganey, N. and Neale, J. (2008) Theorising equipment-sharing in a cohort of Scottish drug users. Health, Risk and Society, 10(6), pp. 599-607. (doi: 10.1080/13698570802533697)

McIntosh, J., Bloor, M. and Robertson, M. (2008) The health benefits of reductions in individuals use of illegal drugs. Journal of Substance Use, 13(4), pp. 247-254. (doi: 10.1080/14659890701802836)

Poliseckia, E. et al. (2008) Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 200(1), pp. 95-101. (doi: 10.1016/j.atherosclerosis.2007.12.005)

Neale, J., Robertson, M. and Bloor, M. (2007) Treatment experienced and treatment naive drug agency clients compared. International Journal of Drug Policy, 18(6), pp. 486-493. (doi: 10.1016/j.drugpo.2006.10.005)

Fonarow, G., Lukas, M., Robertson, M., Colucci, W. and Dargie, H. (2007) Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American Heart Journal, 154, pp. 637-644. (doi: 10.1016/j.ahj.2007.06.002)

O'Reilly, D., Upton, M.N., Caslake, M.J., Robertson, M., Norrie, J., McConnachie, A. , Watt, G.C.M. and Packard, C.J. (2006) Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. Heart, 92(4), pp. 533-535. (doi: 10.1136/hrt.2005.063081)

Kemp, P., Neale, J. and Robertson, M. (2006) Homelessness among problem drug users: prevalence, risk factors and trigger events. Health and Social Care in the Community, 14, pp. 319-328. (doi: 10.1111/j.1365-2524.2006.00624.x)

McKeganey, N., Bloor, M., Robertson, M., Neale, J. and MacDougall, J. (2006) Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study. Drugs: Education, Prevention, and Policy, 13, pp. 537-550. (doi: 10.1080/09687630600871987)

McKeganey, N., Neale, J. and Robertson, M. (2005) Physical and sexual abuse among drug users contacting drug treatment services in Scotland. Drugs: Education, Prevention, and Policy, 12, pp. 223-232. (doi: 10.1080/09687630412331317998)

McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. and Ford, I. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction - Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, pp. 525-530.

McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, N. and Ford, I. (2005) Antiarrythmic effect of carvedilol after acute myocardial infarction. Journal of the American College of Cardiology, 45(4), pp. 525-530. (doi: 10.1016/j.jacc.2004.09.076)

Neale, J. and Robertson, M. (2005) Recent life problems and non-fatal overdose among heroin users entering treatment. Addiction, 100, pp. 168-175. (doi: 10.1111/j.1360.0443.2004.00920.x)

Packard, C.J. et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112, pp. 3058-3065. (doi: 10.1161/CIRCULATIONAHA.105.526848)

Cook, G., Clark, R., Morris, T., Robertson, M., Lucie, N., Anderson, S., Paul, J. and Franklin, I. (2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and clexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126(6), pp. 792-798. (doi: 10.1111/j.1365-2141.2004.05127.x)

McKeganey, N., Morris, Z., Neale, J. and Robertson, M. (2004) What are drug users looking for when they contact drug services: abstinence or harm reduction? Drugs: Education, Prevention, and Policy, 11, pp. 423-435. (doi: 10.1080/09687630410001723229)

Neale, J. and Robertson, M. (2004) Recent cocaine and crack use among new drug treatment clients in Scotland. Drugs: Education, Prevention, and Policy, 11, pp. 79-90. (doi: 10.1080/0968763031000140183)

Neale, J. and Robertson, M. (2003) Comparisons of self-report data and oral fluid testing in detecting drug use amongst new treatment clients. Drug and Alcohol Dependence, 71, pp. 57-64. (doi: 10.1016/S0376-8716(03)00053-X)

Little, S.A., Sproule, M.W., Cowan, M.D., Macleod, K.J., Robertson, M., Love, J.G., Chalmers, G.W., McSharry, C. and Thomson, N. (2002) High resolution computed tomography assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax, 57(3), pp. 247-253. (doi: 10.1136/thorax.57.3.247)

Little, S., Sproule, M., Cowan, M., MacLeod, K., Robertson, M., Love, J., Chalmers, G., McSharry, C. and Thomson, N. (2002) High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax, 57, pp. 247-253.

Millett, D.T., Hallgren, A., Fornell, A.C. and Robertson, M. (1999) Bonded molar tubes: a retrospective evaluation of clinical performance. American Journal of Orthodontics and Dentofacial Orthopedics, 115(6), pp. 667-674.

Millett, D.T., Hallgren, A., Cattanach, D., McFadzean, R., Pattison, J., Robertson, M. and Love, J. (1998) A 5-year clinical review of bond failure with a light cured resin adhesive. Angle Orthodontist, 68(4), pp. 351-356.

Baxter, G.M., Aitchison, F., Sheppard, D., Moss, J., McLeod, M.J., Harden, P.N., Love, J.G., Robertson, M. and Taylor, G. (1996) Colour doppler ultrasound in renal artery stenosis: intrarenal waveform analysis. British Journal of Radiology, 69(825), pp. 810-815. (doi: 10.1259/0007-1285-69-825-810)